Paul Tudor Jones's CLDX Position Overview
Paul Tudor Jones (via Tudor Investment Corp Et Al) currently holds 35,393 shares of Celldex Therapeutics, Inc. (CLDX) worth $1.12 M, representing 0.00% of the portfolio. First purchased in 2023-Q1, this medium-term investment has been held for 12 quarters.
Based on 13F filings, Paul Tudor Jones has maintained a strategic position in CLDX, demonstrating sustained confidence in this investment. Largest addition occurred in Q1 2024, adding 52,842 shares. Largest reduction occurred in Q2 2024, reducing 67,384 shares.
Analysis based on 13F filings available since 2013 Q2
Paul Tudor Jones's Celldex Therapeutics (CLDX) Holding Value Over Time
Track share changes against reported price movement
Quarterly Celldex Therapeutics (CLDX) Trades by Paul Tudor Jones
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | +35,393 | New Buy | 35,393 | $31.72 |
| Q4 2025 | -31,618 | Sold Out | 0 | $0.00 |
| Q3 2025 | +31,618 | New Buy | 31,618 | $25.87 |
| Q2 2025 | -35,141 | Sold Out | 0 | $0.00 |
| Q1 2025 | +2,596 | Add 7.98% | 35,141 | $18.15 |
| Q4 2024 | +32,545 | New Buy | 32,545 | $25.27 |
| Q2 2024 | -67,384 | Sold Out | 0 | $0.00 |
| Q1 2024 | +52,842 | Add 363.38% | 67,384 | $41.97 |
| Q4 2023 | -7,496 | Reduce 34.01% | 14,542 | $39.66 |
| Q3 2023 | -1,637 | Reduce 6.91% | 22,038 | $27.52 |
| Q2 2023 | -3,600 | Reduce 13.20% | 23,675 | $33.93 |
| Q1 2023 | +27,275 | New Buy | 27,275 | $0.04 |
Paul Tudor Jones's Celldex Therapeutics Investment FAQs
Paul Tudor Jones first purchased Celldex Therapeutics, Inc. (CLDX) in Q1 2023, acquiring 27,275 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Paul Tudor Jones has held Celldex Therapeutics, Inc. (CLDX) for 12 quarters since Q1 2023.
Paul Tudor Jones's largest addition to Celldex Therapeutics, Inc. (CLDX) was in Q1 2024, adding 67,384 shares worth $2.83 M.
According to the latest 13F filing for Q1 2026, Paul Tudor Jones's firm, Tudor Investment Corp Et Al, owns 35,393 shares of Celldex Therapeutics, Inc. (CLDX), valued at approximately $1.12 M.
As of the Q1 2026 filing, Celldex Therapeutics, Inc. (CLDX) represents approximately 0.00% of Paul Tudor Jones's publicly disclosed stock portfolio, making it one of their key holdings.
Paul Tudor Jones's peak holding in Celldex Therapeutics, Inc. (CLDX) was 67,384 shares, as reported at the end of Q1 2024.